<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02542397</url>
  </required_header>
  <id_info>
    <org_study_id>LCI-NOS-PAIN-001</org_study_id>
    <nct_id>NCT02542397</nct_id>
  </id_info>
  <brief_title>LCI-NOS-PAIN-001: A Prospective, Pharmacogenomic-Driven Study of Pain Management in Oncology Outpatients</brief_title>
  <official_title>LCI-NOS-PAIN-001: A Prospective, Pharmacogenomic-Driven Pilot Study of Pain Management in Oncology Outpatients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jai Patel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atrium Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      About half of all cancer patients seen in oncology clinics have pain at initial assessment;&#xD;
      pain relief within a one-month period is seen in approximately one third of these patients&#xD;
      and pain worsening in about one fifth. Risk factors for under-treatment of cancer pain&#xD;
      include age older than 65 years, minority status, and inadequate pain assessment practices.&#xD;
      There is a need for better methods of opioid drug/dose selection and identification of risk&#xD;
      factors for worsening pain. Pharmacogenomic approaches offer insight into the genetic&#xD;
      variables that impact the pharmacokinetic and pharmacodynamic behavior of opioids.&#xD;
      Translating pharmacogenomic results into actionable prescribing decisions may ultimately&#xD;
      enable a personalized approach to pain management, increasing the chance of significant pain&#xD;
      improvement. Cancer outpatients with uncontrolled malignant pain will be offered a&#xD;
      pharmacogenomic test through participation in the study. The results of this test will be&#xD;
      used to modify their pain regimen, if applicable.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects will be assessed and prescribed a pain regimen as part of standard practice at&#xD;
      the initial visit. Subjects will provide a buccal swab for pharmacogenomic testing and will&#xD;
      be discharged on their initial pain regimen.&#xD;
&#xD;
      After the initial visit, subjects will be asked to rate their daily pain on a scale of 0-10.&#xD;
      A coordinator will follow up with the subject within 7 days (Assessment #1). Subjects will be&#xD;
      asked to report information about their pain scores, pain medication use, and caffeine&#xD;
      intake, in addition to any bothersome symptoms. Subjects who continue to have &quot;uncontrolled&#xD;
      pain&quot;, are experiencing bothersome symptoms, and/or requests for a drug/dose modification&#xD;
      will have his/her drug/dose modified using the pharmacogenomic test results. If the subject&#xD;
      has had significant pain improvement, stable mild pain and/or is satisfied with their level&#xD;
      of pain at the assessment (regardless of pain score), he/she will be recommended to continue&#xD;
      the current drug/dose and return to clinic on day 30 for the final follow-up. Subjects will&#xD;
      be told to call if their pain becomes intolerable or if they experience bothersome symptoms&#xD;
      after Assessment #1 for further drug/dose modification if needed prior to day 30.&#xD;
&#xD;
      The coordinator will follow up with the subjects receiving a drug/dose modification after&#xD;
      another 7 days (Assessment #2). Subjects who have now had significant pain improvement,&#xD;
      stable mild pain, and/or are satisfied with their level pain at the assessment (regardless of&#xD;
      pain score) will continue on the same regimen. If the subjects' pain is still &quot;uncontrolled&quot;,&#xD;
      they are experiencing bothersome symptoms, and/or they request a drug/dose modification,&#xD;
      their drug/dose will be modified accordingly. Subjects will be told to call if needed,&#xD;
      otherwise they will be seen in clinic on day 30 (Final Assessment).&#xD;
&#xD;
      If the subject experiences intolerable pain prior to any scheduled assessment, the subject&#xD;
      will call for appropriate drug/dose modification.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Early study closure due to limited internal resources to continue enrollment.&#xD;
  </why_stopped>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">June 2019</completion_date>
  <primary_completion_date type="Actual">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Enrolled subjects all receive pharmacogenomic testing with the intention of guiding pain management. This single-arm trial is testing against a published historical control.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Pain Improvement as Measured Using the Edmonton Symptom Assessment Scale (ESAS) From Baseline Assessment (Day 0) to Final Assessment on Day 30 +/- 7</measure>
    <time_frame>Enrollment to Final Assessment (30 +/- 7 days from Baseline Assessment (Day 0))</time_frame>
    <description>Proportion of subjects achieving significant pain improvement over a one month period (30 days +/- 7) (defined as a ≥ 2 point decrease from baseline pain score on an 11-point scale [0-10]) in oncology outpatients receiving pharmacogenomic testing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morphine Equivalent Daily Doses (MEDD) in Milligrams</measure>
    <time_frame>Final Assessment (30 +/- 7 days from Baseline Assessment (Day 0))</time_frame>
    <description>Describe the distribution of morphine equivalent daily dose (MEDD) in the evaluable population. The MEDD was calculated and recorded at the Final Assessment for each subject by converting the subject's total daily opioid consumption at the Final Assessment to morphine equivalent doses using the following website: http://www.globalrph.com/narcoticonv.htm (widely used across many health systems for drug/dose conversions and fully referenced).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With an Actionable Genotype, Defined as the Presence of Any Mutation(s) That is (Are) Used to Guide a Drug/Dose Modification</measure>
    <time_frame>Enrollment to Final Assessment (30 +/- 7 days from Baseline Assessment (Day 0))</time_frame>
    <description>An actionable genotype is defined as the presence of at least one mutation that is used to guide a drug/dose modification during Assessment 1, Assessment 2, or any unscheduled visit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Malignant Tumor of Ill-defined Site</condition>
  <arm_group>
    <arm_group_label>Pharmacogenomic Testing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pharmacogenomic test results to guide drug/dose modifications</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Pharmacogenomic Testing</intervention_name>
    <description>Pharmacogenomic test results to guide drug/dose modifications</description>
    <arm_group_label>Pharmacogenomic Testing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presence of uncontrolled malignant pain (score of greater than or equal to 2 on an 11&#xD;
             point scale [0-10]) as diagnosed and assessed by the Investigator, using the Edmonton&#xD;
             Symptom Assessment Scale (ESAS).&#xD;
&#xD;
          -  Documentation of any stage of cancer of any tumor location (solid or hematological).&#xD;
&#xD;
          -  At least 18 years of age.&#xD;
&#xD;
          -  Either nociceptive or neuropathic pain.&#xD;
&#xD;
          -  Able to understand and be willing to sign the study consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inpatient service at baseline visit.&#xD;
&#xD;
          -  Significant dysphagia and inability to swallow oral medications as determined by the&#xD;
             Investigator.&#xD;
&#xD;
          -  Active or recent (within one year) drug and/or alcohol abuse as determined by the&#xD;
             Investigator.&#xD;
&#xD;
          -  Significant baseline cognitive impairment, as determined by the Investigator. Known&#xD;
             (anaphylactic) hypersensitivity to any opioid.&#xD;
&#xD;
          -  Severe oral mucositis that would impair proper buccal testing as determined by the&#xD;
             Investigator.&#xD;
&#xD;
          -  Receiving concurrent rehabilitation medicine care, nociception modulation (e.g.,&#xD;
             electrical stimulation), use of modalities with physiologic effects that indirectly&#xD;
             influence nociception (e.g., light, laser therapy), or any other non-pharmacologic&#xD;
             approaches to pain management other than exercise, rest, ice, compression, and&#xD;
             elevation (RICE).&#xD;
&#xD;
          -  Presence of major psychiatric disorders as determined by the Investigator.&#xD;
&#xD;
          -  Receiving active treatment or prophylaxis for epilepsy.&#xD;
&#xD;
          -  Unable or unwilling to sign the study consent form.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jai Patel, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Levine Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 2, 2015</study_first_submitted>
  <study_first_submitted_qc>September 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2015</study_first_posted>
  <results_first_submitted>January 14, 2021</results_first_submitted>
  <results_first_submitted_qc>January 14, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 2, 2021</results_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Atrium Health</investigator_affiliation>
    <investigator_full_name>Jai Patel</investigator_full_name>
    <investigator_title>Chief, Pharmacology Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 6, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT02542397/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pharmacogenomic Testing</title>
          <description>Cancer outpatients with uncontrolled malignant pain undergo a pharmacogenomic panel (by buccal swab) with the intent of informing pain management.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75">75 subjects were enrolled to the study (i.e., submitted buccal swab).</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59">54 enrolled subjects provided pain scores at baseline and final assessments within 30 +/- 7 days.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline analysis population is defined as all enrolled subjects (i.e., submitted buccal swab for pharmacogenomic testing).</population>
      <group_list>
        <group group_id="B1">
          <title>Pharmacogenomic Testing</title>
          <description>Cancer outpatients with uncontrolled malignant pain undergo a pharmacogenomic panel (by buccal swab) with the intent of informing pain management.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="30" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cancer type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Breast</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Gastrointestinal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Gynecologic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multiple Myeloma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Thoracic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Genitourinary</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Cutaneous malignancies</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage of cancer (as captured from the Medical Record and determined by the TNM system of the AJCC)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>1 or 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 or 4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Pain Improvement as Measured Using the Edmonton Symptom Assessment Scale (ESAS) From Baseline Assessment (Day 0) to Final Assessment on Day 30 +/- 7</title>
        <description>Proportion of subjects achieving significant pain improvement over a one month period (30 days +/- 7) (defined as a ≥ 2 point decrease from baseline pain score on an 11-point scale [0-10]) in oncology outpatients receiving pharmacogenomic testing.</description>
        <time_frame>Enrollment to Final Assessment (30 +/- 7 days from Baseline Assessment (Day 0))</time_frame>
        <population>The evaluable population is defined as those enrolled subjects providing pain scores at Baseline Assessment (Day 0) and Final Assessment (Day 30 +/- 7).</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacogenomic Testing: Evaluable Population</title>
            <description>Enrolled subjects providing pain scores at Baseline Assessment (Day 0) and Final Assessment (Day 30 +/- 7).</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Pain Improvement as Measured Using the Edmonton Symptom Assessment Scale (ESAS) From Baseline Assessment (Day 0) to Final Assessment on Day 30 +/- 7</title>
          <description>Proportion of subjects achieving significant pain improvement over a one month period (30 days +/- 7) (defined as a ≥ 2 point decrease from baseline pain score on an 11-point scale [0-10]) in oncology outpatients receiving pharmacogenomic testing.</description>
          <population>The evaluable population is defined as those enrolled subjects providing pain scores at Baseline Assessment (Day 0) and Final Assessment (Day 30 +/- 7).</population>
          <units>proportion of evaluable participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".5556" lower_limit=".4140" upper_limit=".6908"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>A single-stage design was used to test the hypothesis that the pain improvement rate, assessed by the Edmonton Symptom Assessment Scale, is &lt;= 0.30. Our study targeted enrollment of 71 evaluable subjects for the final analysis; 54 subjects met the criteria at study closure. Assuming a one-sided alpha=0.10 significance level, 71 evaluable subjects would provide approximately 90% power to reject the null hypothesis (based on an exact binomial test) assuming the true pain improvement rate is 0.45.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>It has been reported that, based on the Edmonton Symptom Assessment Scale (ESAS) pain scale, about 30% of cancer patients receiving standard of care pain management experienced &gt;= 2-point improvement in pain score between visits [Ref].&#xD;
Ref: Scharpf, J., et al., The role of pain in head and neck cancer recurrence and survivorship. Arch Otolaryngol Head Neck Surg, 2009. 135(8): p. 789-94.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was alpha = 0.10.</p_value_desc>
            <method>Exact binomial test of proportions</method>
            <param_type>Exact binomial proportion</param_type>
            <param_value>.5556</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.4140</ci_lower_limit>
            <ci_upper_limit>.6908</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morphine Equivalent Daily Doses (MEDD) in Milligrams</title>
        <description>Describe the distribution of morphine equivalent daily dose (MEDD) in the evaluable population. The MEDD was calculated and recorded at the Final Assessment for each subject by converting the subject's total daily opioid consumption at the Final Assessment to morphine equivalent doses using the following website: http://www.globalrph.com/narcoticonv.htm (widely used across many health systems for drug/dose conversions and fully referenced).</description>
        <time_frame>Final Assessment (30 +/- 7 days from Baseline Assessment (Day 0))</time_frame>
        <population>The evaluable population is defined as those enrolled subjects providing pain scores at Baseline Assessment (Day 0) and Final Assessment (Day 30 +/- 7).</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacogenomic Testing: Evaluable Population</title>
            <description>Enrolled subjects providing pain scores at baseline assessment and a final assessment within 30 +/- 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Morphine Equivalent Daily Doses (MEDD) in Milligrams</title>
          <description>Describe the distribution of morphine equivalent daily dose (MEDD) in the evaluable population. The MEDD was calculated and recorded at the Final Assessment for each subject by converting the subject's total daily opioid consumption at the Final Assessment to morphine equivalent doses using the following website: http://www.globalrph.com/narcoticonv.htm (widely used across many health systems for drug/dose conversions and fully referenced).</description>
          <population>The evaluable population is defined as those enrolled subjects providing pain scores at Baseline Assessment (Day 0) and Final Assessment (Day 30 +/- 7).</population>
          <units>milligrams</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="0" upper_limit="789"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With an Actionable Genotype, Defined as the Presence of Any Mutation(s) That is (Are) Used to Guide a Drug/Dose Modification</title>
        <description>An actionable genotype is defined as the presence of at least one mutation that is used to guide a drug/dose modification during Assessment 1, Assessment 2, or any unscheduled visit.</description>
        <time_frame>Enrollment to Final Assessment (30 +/- 7 days from Baseline Assessment (Day 0))</time_frame>
        <population>The evaluable population is defined as those enrolled subjects providing pain scores at Baseline Assessment (Day 0) and Final Assessment (Day 30 +/- 7).</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacogenomic Testing: Evaluable Population</title>
            <description>Enrolled subjects providing pain scores at baseline assessment and a final assessment within 30 +/- 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With an Actionable Genotype, Defined as the Presence of Any Mutation(s) That is (Are) Used to Guide a Drug/Dose Modification</title>
          <description>An actionable genotype is defined as the presence of at least one mutation that is used to guide a drug/dose modification during Assessment 1, Assessment 2, or any unscheduled visit.</description>
          <population>The evaluable population is defined as those enrolled subjects providing pain scores at Baseline Assessment (Day 0) and Final Assessment (Day 30 +/- 7).</population>
          <units>percentage of evaluable participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33" lower_limit="21.09" upper_limit="47.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From enrollment date (i.e., buccal swab is collected) (Day 0) to the final study assessment on Day 30 +/- 7.</time_frame>
      <desc>Opioid-related adverse events were summarized and attributed based on Common Terminology Criteria for Adverse Events version 4.03. Adverse events deemed &quot;possibly&quot;, &quot;probably&quot;, and &quot;definitely related&quot; to opioid use by the Investigator were summarized for the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pharmacogenomic Testing</title>
          <description>Cancer outpatients with uncontrolled malignant pain undergo a pharmacogenomic panel (by buccal swab) with the intent of informing pain management.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, Weakness in joints</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Injury, poisoning and procedural complications - Other, Chin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Concentration impairment</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, Change in mental status</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hallucinations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early study closure due to limited internal resources to continue enrollment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Danielle M Boselli</name_or_title>
      <organization>Atrium Health/Levine Cancer Institute, Department of Cancer Biostatistics</organization>
      <phone>12017903385</phone>
      <email>Danielle.Boselli@AtriumHealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

